The most common reply to Issue #1 was some version of "so what do we charge now?" Fair. This issue is the answer.
📡 The Radar
1. The manufacturer price war has a floor now, and it's $149.
NovoCare's cash price for the Wegovy pill is $149 a month at the starting dose, $199 at 4 mg, and $299 at 9 and 25 mg. The pen is $349 across the standard doses, $399 for the high dose, with a $199 new-patient offer for the first two fills that runs through December 31 (NovoCare pricing page). Lilly's answer is Zepbound vials at $299 for 2.5 mg, $399 for 5 mg, and $449 for every dose above that, but only if the patient refills within 45 days. Miss the window and the maintenance doses reset to $499 to $699 (LillyDirect Zepbound page).
What it means for your clinic: pull a cash quote from each manufacturer portal this week and write it on the whiteboard. That number is your patient's anchor now, not your competitor's. Also note the 45-day refill condition. Patients who lapse pay hundreds more, which makes your program's adherence follow-up worth real money to them.
2. The 503B door is still open a crack. Don't lean on it.
FDA proposed on April 30 to keep semaglutide, tirzepatide, and liraglutide off the 503B bulks list, finding no clinical need to compound them from bulk when approved product is available (FDA announcement). Comments closed at the end of June, then an extension ran to July 31 (Federal Register notice). As of this week there is no final determination and no published effective date.
What it means: calendar the effective dates, not the headlines. A revenue line that assumes 503B compounded GLP-1 economics has an expiration date the agency hasn't printed yet. Model your program without it and treat anything you still get as a bonus.
3. FDA just told the peptide supply chain who it's watching.
Two things in one month. On the enforcement side, FDA posted warning letters dated August 24 to a group of online peptide sellers, including Royal Peptides, for marketing unapproved injectable drugs behind "research use only" labels (Royal Peptides warning letter). On the rulemaking side, the Pharmacy Compounding Advisory Committee that recommended six peptides for 503A in July already has a second round announced: FDA says the committee will meet before the end of February 2027 to consider five more, cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF (FDA meeting announcement).
What it means: the supply side of "where did this vial come from" is now an active federal target, not a hypothetical. And an advisory vote authorizes nothing. If a vendor tells you a peptide is "approved for compounding now," ask them for the Federal Register citation. There isn't one yet.
🔭 The Watchlist
FTC's click-to-cancel rule was thrown out by the Eighth Circuit last summer on procedural grounds, and the agency has started the rulemaking over (FTC Negative Option Rule page). The substance is coming back. If your membership has an early-termination fee or a cancel-by-phone-only policy, that is a business decision worth revisiting before a rule forces it. More on this in a later issue.
🔧 The Operator Lesson: the membership stack that survives a price war
Here is the test. If the manufacturer halves the drug price tomorrow, does your P&L survive?
If your answer is no, your revenue is the drug's revenue, and you are a reseller with a medical license. Resellers lose price wars to the manufacturer every time.
The structure we run has three separate payments, and the drug is the smallest lever:
The evaluation. A paid provider visit up front. It funds the clinical work, filters for people who are serious, and is the one line item the manufacturer cannot undercut.
The membership. A flat monthly fee for the program: monitoring, titration decisions, lab review, messaging, accountability. This is the product. The drug is an input to it.
The medication at transparent retail. Whatever the pharmacy or manufacturer charges, passed through with the markup stated plainly. When NovoCare drops to $149, your patient pays $149. Your membership fee didn't change.
Blended across our members, the retained program revenue lands around $259 per member per month after medication cost. Break-even on the program's fixed costs is in the low thirties of members. Every member past that is margin the price war can't touch, because the price war is happening in line three.
Run your own numbers this way: strip medication revenue out entirely, add up what's left per member, and divide your fixed monthly costs by it. That quotient is how many members you need to keep the lights on with zero drug margin. If it's a number you can hit, the price war is someone else's problem.
Before you go
New here? The Processor-vs-EMR Reconciliation Worksheet from Issue #1 is still free for subscribers. It's the same monthly pass that surfaced $58,000 in declined charges at one practice. Download it →
What does your membership actually include? Hit reply and tell us. We read everything, and the answers are shaping the Toolkit.
— Devin & Ryan
The Clinic Brief is business and regulatory information, not legal or medical advice. Talk to qualified healthcare counsel about your specific situation.